We're not expecting any changes to our fair value estimates for vaccine manufacturers, however, as most of the firms in our coverage with vaccine candidates have already stated that selling prices would be at a not-for-profit level.
Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.
Our coronavirus infection and fatality assumptions have edged down as we settle closer to control.
We're slightly raising our fair value estimate for the wide-moat firm.
We're maintaining our $82 fair value estimate for the wide-moat firm while we await more data from the testing.
Moats, valuations, and dividends look attractive in the market pullback.
We discuss our latest views on stopping the spread of the virus as well as the economic implications.
Our outlook on how the U.S. will cope during and after the shutdown.
Karen Andersen and Preston Caldwell give us their latest perspectives on healthcare and energy.
It already had a solid lineup even before news of its potential COVID-19 treatment.
The hit to 2020 should be significant, but we see minimal long-term economic impact, and the treatment pipeline is progressing.
We don't assume any significant long-term financial impact from the outbreak.
Morningstar's Karen Andersen explains how ESG issues affect Big Pharma and biotech companies.
Morningstar and Sustainalytics offer complementary methodologies.
Details on Alzheimer's drug candidate are encouraging, but uncertainty remains.
Recent results from some of the most undervalued large drugmakers we cover.
We assign a 30% probability of approval of the wide-moat firm's Alzheimer's drug.
These industries are the most undervalued in the healthcare sector, owing to potential U.S. drug pricing reforms coming out of Washington.
We like Roche, which has been less exposed to rebates and can defend its growth.
Even after recent failed drug trials, we think the company’s undervalued.
We think the market underappreciates some large pharma and biotech names.
We continue to believe that the NASH opportunity is not fully baked into shares.
A broad array of oncology and autoimmune programs gives the company a larger margin of error.
We think the deal is strategically and financially positive.
The current CEO of Roche's pharmaceutical division, Daniel O'Day, will leave Roche at the end of 2018 and for Gilead, cementing the firm's oncology commitment.
The narrow-moat firm has multiple data and launch catalysts through 2020 leading to our higher than consensus projections.
There's too much uncertainty to assume a significant hit to prices.
The wide-moat drugmaker's pipeline will allow it to grow in the face of biosimilar competition.
Wide-moat Gilead and no-moat Intercept have promising treatments for liver disease that could see more than $2 billion in peak sales.
We expect the pharma company to continue earning excess returns.
These manufacturing experts look undervalued today.
Alzheimer's therapy shows promising results.
The wide-moat drugmaker's cash pile can support acquisitions to bolster growth in the face of biosimilar and branded pressure.
The failure of their cancer immunotherapy combination is a bigger blow to Incyte than to Merck.
The rumored deal is somewhat of a surprise, but it could make strategic sense.
A growing portfolio of rare-disease drugs digs a moat for the company.
The narrow-moat biotech firm's financial health doesn't worry us as its approved therapies help drive growth.
We think many of its drugs are relatively more resistant to patent cliffs or sales pressure from generics.
We're raising our fair value estimate on the narrow-moat firm after the unveiling of a new cancer product.
Sotagliflozin's side effects and competitor data lead to a near $10 cut.
We think the wide-moat firm can counter biosimilar competition and maintain its strong position.
We don't think the current price accounts for the company's pipeline.
Though we’ve slightly reduced our fair value estimate, we see Roche’s wide economic moat as stable, given the firm’s dominance in branded cancer therapies and in vitro diagnostics globally.
The biotech giant trades at a wide discount to what we think it's worth.
We continue to see the company's broad portfolio and newer drugs as providing a wide economic moat and a buffer to biosimilar threats to the older Enbrel and Neulasta franchises.
Our bullish view on potential sales of the first drug of this development-stage biotech is balanced by the expected ramp-up in operating expenses in 2017.
Five-star-rated Amgen's wide moat is supported by a diverse portfolio that will shield it from biosimilar headwinds.
Despite CEO uncertainty, we remain confident in the firm's wide moat and competitive advantages in neurology.
Its MS market dominance and neurology pipeline support a wide moat.
We think the market is underestimating wide-moat Biogen’s potential to expand its neurology portfolio beyond multiple sclerosis.